ArticleJournal of cancer research and clinical oncology2020
Safety and efficacy of CT-guided radioactive iodine-125 seed implantation assisted by a 3D printing template for the treatment of thoracic malignancies.
Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- 3D printing in palliative medicine: systematic review.BMJ supportive & palliative care · 2024Pooled it
- Local efficacy and safety of CT-guided Iodine-125 seed implantation in the treatment of recurrent malignant tumors: a retrospective study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Dose-effect relationship of D90 in iodine-125 seed implantation for advanced lung cancer: gradient-based efficacy and survival outcome.BMC cancer · 2026Article
- Clinical Outcomes and Individualized Seed Implantation Planning for Iodine-125 Seeds Brachytherapy in Lymph Node Metastases.Journal of Cancer · 2026Article
- Review
- Comparative study for CT-guidedBMC medical imaging · 2025Article
- Recent progress in radioactive seed implantation brachytherapy of non-small cell lung cancer: a narrative review.Journal of thoracic disease · 2024Review
- Characteristics of preplan-based three-dimensional individual template-guided brachytherapy compared to freehand implantation.Journal of applied clinical medical physics · 2023Article
- Stereotactic ablative brachytherapy with or without assistance of 3D-printing templates for inoperable locally recurrent or oligometastatic soft-tissue sarcoma: a multicenter real-world study.American journal of cancer research · 2023Article
- Study on the application of 3D printing head film fixation technology in cranial radiotherapy.Journal of Cancer · 2023Article
- I-125 seeds brachytherapy combined with immunotherapy for MET amplification in non-small cell lung cancer from clinical application to related lncRNA mechanism explore: a case report.Frontiers in cell and developmental biology · 2023Article
- A comparative study of dosimetric parameters of 3D-printed non-coplanar template-assisted CT-guided iodine-125 seed implantation brachytherapy in patients with inguinal lymph node metastatic carcinomas.Journal of contemporary brachytherapy · 2022Article
- Safety and efficacy of stereotactic ablative brachytherapy as a salvage therapy for recurrent chest wall cancer: A retrospective, multicenter study.Frontiers in oncology · 2022Article
- Dosimetry verification of three-dimensional printed polylactic acid template-guided precisionJournal of applied clinical medical physics · 2021Article
- Long-Term Outcomes of Personalized Stereotactic Ablative Brachytherapy for Recurrent Head and Neck Adenoid Cystic Carcinoma after Surgery or External Beam Radiotherapy: A 9-Year Study.Journal of personalized medicine · 2021Article
- Stereotactic Ablative Brachytherapy: Recent Advances in Optimization of Radiobiological Cancer Therapy.Cancers · 2021Review
- The accuracy and dosimetric analysis of 3D-printing non-coplanar template-assisted iodine-125 seed implantation for recurrent chest wall cancer.Journal of contemporary brachytherapy · 2021Article
- Safety and efficacy of 3D-printed templates assisted CT-guided radioactive iodine-125 seed implantation for the treatment of recurrent cervical carcinoma after external beam radiotherapy.Journal of gynecologic oncology · 2021Article
- Accuracy and dosimetric parameters comparison of 3D-printed non-coplanar template-assisted computed tomography-guided iodine-125 seed ablative brachytherapy in pelvic lateral recurrence of gynecological carcinomas.Journal of contemporary brachytherapy · 2021Article
- Dosimetric comparison of computed tomography-guided iodine-125 seed implantation assisted with and without three-dimensional printing non-coplanar template in locally recurrent rectal cancer: a propensity score matching study.Journal of contemporary brachytherapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo ascertain the safety and efficacy of radioactive iodine-125 seed implantation (RISI) for the treatment of thoracic tumors.
methodsClinical patients with primary or metastatic tumors in the chest treated with RISI were analyzed. The RISI process included the following stages: preoperative planning, template design and 3D printing, CT-guided RISI assisted by a template, and postoperative dosimetric verification. The prescribed dose was ≥ 80 Gy. The main analytic measures were the local control (LC) rate and toxicity.
resultsFrom April 2015 to July 2018, a total of 92 patients, including 41 with lung cancer and 51 with lung metastases, were analyzed. The median lesion diameter was 5 cm. The median postoperative D90 was 142.6 Gy. The median follow-up was 10.7 months. The overall survival rates at 1 year and 3 years were 59.7% and 22.2%, respectively. The LC rates at 1 year and 3 years were 64.9% and 32.8%, respectively. The LC rates at 3 years for patients with D90 < 140 Gy and D90 > 140 Gy were 23.1% and 54.3%, respectively (P = 0.014). The LC rate of metastatic lung cancer was more favorable than that of primary lung cancer. The multivariate analyses showed that the dose and lesion type were independent factors for LC (P < 0.05). No factors were related to OS. The incidence of pneumothorax and hemoptysis was 35.8% and 3.2%, respectively. Few cases of radiotherapy-related toxicity effects were observed.
conclusionsRISI may be safe and efficacious and is associated with few complications during the treatment of thoracic tumors. If patients need local treatment and surgery or radiotherapy is not available, RISI could be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.